Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
MNKD

MNKD - MannKind Corp Stock Price, Fair Value and News

$5.64+0.05 (+0.89%)
Market Closed

58/100

MNKD

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

58/100

MNKD

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$5.75

Target 3M

$5.53

Target 6M

$5.61

MNKD Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MNKD Price Action

Last 7 days

-1.2%

Last 30 days

-2.2%

Last 90 days

1.6%

Trailing 12 Months

-7.7%

MNKD RSI Chart

MNKD Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

MNKD Valuation

Market Cap

1.7B

Price/Earnings (Trailing)

59.24

Price/Sales (Trailing)

5.52

EV/EBITDA

32.98

Price/Free Cashflow

39.92

MNKD Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$5.75

Target 3M

$5.53

Target 6M

$5.61

MNKD Fundamentals

MNKD Revenue

Revenue (TTM)

313.8M

Rev. Growth (Yr)

17.2%

Rev. Growth (Qtr)

7.32%

MNKD Earnings

Earnings (TTM)

29.2M

Earnings Growth (Yr)

-30.87%

Earnings Growth (Qtr)

1.1K%

MNKD Profitability

EBT Margin

9.81%

Return on Equity

-65.62%

Return on Assets

5.91%

Free Cashflow Yield

2.51%

MNKD Investor Care

Shares Dilution (1Y)

11.35%

Diluted EPS (TTM)

0.1

MNKD Alerts

  • 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025297.6M301.7M313.8M0
2024224.6M248.4M267.2M285.5M
2023128.4M158.1M176.5M199.0M
202270.0M65.6M76.2M99.8M
202166.3M74.5M81.4M75.4M
202061.8M61.9M62.7M65.1M
201941.8M53.0M63.1M63.0M
201812.2M13.9M16.4M27.9M
2017134.0M93.3M52.5M11.7M
201600131.1M174.8M
20120043.7M87.4M
201182.3K71.5K60.8K50.0K
201000093.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About MannKind Corp

MNKD
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DP Treprostinil, an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease, and idiopathic pulmonary and cystic fibrosis. In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
 CEO
 WEBSITEmannkindcorp.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES391

MannKind Corp Frequently Asked Questions

MNKD is the stock ticker symbol of MannKind Corp. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of MannKind Corp is 1.73 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check MNKD's fair value in chart for subscribers.

The fair value guage provides a quick view whether MNKD is over valued or under valued. Whether MannKind Corp is cheap or expensive depends on the assumptions which impact MannKind Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MNKD.

As of Wed Jan 28 2026, MNKD's PE ratio (Price to Earnings) is 59.24 and Price to Sales (PS) ratio is 5.52. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MNKD PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, MannKind Corp has provided 0.012 (multiply by 100 for percentage) rate of return.